A carregar...
Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice
Idelalisib is a first-in-class oral selective inhibitor of phosphatidylinositol 3-kinase delta, which is selectively expressed in hematopoietic cells, where it is critical to B-cell receptor signaling and B-cell development and function. Idelalisib is approved in the United States for the treatment...
Na minha lista:
| Publicado no: | J Adv Pract Oncol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Harborside Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5866127/ https://ncbi.nlm.nih.gov/pubmed/29588866 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|